

**Specialist Advisory Committees**

Objective advice to Pharmac

www.pharmac.govt.nz

**Immunisation Advisory Committee Provisional recommendations 25 May 2026**

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

The Immunisation Advisory Committee discussed multiple applications in progress for meningococcal vaccines. The provisional recommendations share the main outcomes of those discussions. Further information and updates for all applications discussed will be explained in the full meeting record.

**Summary of Provisional Recommendations**

<b>Pharmaceutical and Indication</b>	<b>Provisional Recommendation</b>
<a href="#">Pertussis vaccine</a> widened access for parents and primary caregivers of infants admitted to neonatal intensive care unit or specialist baby care units, within the context of vaccines and immunisation, subject to criteria	High priority
<a href="#">Meningococcal ACWY vaccine</a> widened access to include one dose for children 1 to 4 years of age inclusive, within the context of vaccines and immunisation (to supersede all previous recommendations for this age group)	High priority
<a href="#">Meningococcal ACWY vaccine</a> widened access to include one dose and one booster dose after 5 years, for adolescents or young adults 14 to 21 years of age inclusive, within the context of vaccines and immunisation, subject to criteria (to supersede all previous recommendations for this age group)	High priority
<a href="#">Meningococcal MenB</a> and <a href="#">MenACWY</a> vaccines widened access to provide a booster dose for adolescents in an eligible setting, within the context of vaccines and immunisation, subject to the eligibility criteria	High priority
<a href="#">Hepatitis A vaccination</a> for the immunisation of people living with HIV, within the context of vaccines and immunisation	Declined
<a href="#">Hepatitis A vaccination</a> for the immunisation of people living with HIV who are at increased risk, within the context of vaccines and immunisation	Declined
<a href="#">Clesrovimab</a> for all infants at birth or in their first RSV season, and for high-risk infants entering their second RSV season, within the context of vaccines and immunisation, subject to criteria	High priority
<a href="#">RSVpreF vaccine</a> (Abrysvo) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in infants by active immunisation of pregnant individuals, within the context of vaccines and immunisation, subject to criteria	High priority
<a href="#">RSVpreF vaccine</a> (Abrysvo) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older, within the context of vaccines and immunisation, subject to criteria	Medium priority

<a href="#">RSVpreF vaccine</a> (Abrysvo) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 to 74 years with eligible comorbidities and all adults 75 years of age and older, within the context of vaccines and immunisation, subject to criteria	High priority
<a href="#">RSVpreF vaccine</a> (Abrysvo) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in people who are immunocompromised, within the context of vaccines and immunisation	Deferred*

\*Deferred – the Committee has recommended that the application be deferred until there is updated/additional clinical evidence available to support this application

[More information about the agenda items considered at the recent Immunisation Advisory Committee meeting can be found on the Pharmac website](#)

Released 3 July 2026